Stockscreener 앱 받기
5.80
0.87%
0.05
시간 외 거래:
5.80
전일 마감가:
$5.75
열려 있는:
$5.64
하루 거래량:
26,864
Relative Volume:
0.37
시가총액:
$533.15M
수익:
$163.13M
순이익/손실:
$-34.75M
주가수익비율:
-11.26
EPS:
-0.5152
순현금흐름:
$-231.66M
1주 성능:
+3.20%
1개월 성능:
-9.09%
6개월 성능:
+33.93%
1년 성능:
-18.65%
1일 변동 폭
$5.64
$5.97
1주일 범위
$5.4289
$5.97
52주 변동 폭
$3.62
$8.661
발네바 Stock (VALN) Company Profile
VALN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
5.80 | 533.15M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
발네바 Stock (VALN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-03 | 개시 | H.C. Wainwright | Buy |
발네바 주식(VALN)의 최신 뉴스
[Valneva SE] Declaration of shares and voting rights - GlobeNewswire Inc.
Valneva SE earnings missed by $0.01, revenue topped estimates - Investing.com
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
Valneva SE Company Investigated by the Portnoy Law Firm - GlobeNewswire
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com India
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
H.C. Wainwright maintains Buy on Valneva with $17 price target - Investing.com
Valneva SE ADR’s Banking’s 100-Day Moving Average at 5.61: Will the Stock Break Through? - investchronicle.com
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - Business Wire
Valneva SE earnings missed by $0.32, revenue fell short of estimates - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation. - Markets Insider
ATTENTION VALN SHAREHOLDERS: Investors who lost money on Valneva SE are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation - Markets Insider
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - Markets Insider
VALN Investors Have Opportunity to Join Valneva SE Fraud Investi - GuruFocus
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy - Investing.com
Déclaration d'actions et de droits de vote de la société Valneva SE - GlobeNewswire Inc.
Valneva stock holds $18 target on UK vaccine nod - Investing.com
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
발네바 (VALN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.70%
자본화:
|
볼륨(24시간):